Evaluation of the efficacy, safety and tolerability of zerlasiran (SLN360) in adults with elevated Lp(a) at high risk of atherosclerotic cardiovascular disease (ASCVD) events
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
